Comparison of Anesthetic Efficacy of Bilateral and Unillateral Application of Kovacaine Mist in Healthy Volunteers

St. Renatus

Status and phase: Completed; Phase 1

Conditions: Anesthesia

Treatments: Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%; Drug: Placebo spray

Study type: Interventional

Funder types: Industry

Identifiers

NCT02457806

SR 2-04

Details and patient eligibility

About

To compare the efficacy of Kovacaine Mist administered bilaterally to that of Kovacaine Mist administered unilaterally with respect to global profound pulpal anesthesia in target teeth numbers 4-13.

Full description

Qualified and consenting healthy subjects will be randomly assigned in a double-blind manner to sequences of four randomly ordered study periods with inter-treatment "washout" periods of 3 to 14 days. The four study regimens, which will be applied in random order will be:

• Regimen1. Three sprays of Kovacaine Mist in each nostril (bilateral dosing);
• Regimen 2. Three sprays of Kovacaine Mist in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing);
• Regimen 3. Three sprays of Kovacaine Mist in the left nostril and three sprays of placebo in the right nostril (left-sided unilateral dosing);
• Regimen 4. Three sprays of placebo in each nostril (placebo dosing).

During each testing period, eight representative maxillary teeth (#s 3, 4, 6, 8, 9, 11, 13 and 14) will be assessed for anesthesia using standard EPT testing. EPT testing will be conducted on the eight representative teeth at the following time points (minutes relative to the first spray of study drug): T-5, T3, T7, T11, T16, T21, T26T31, T41, T51, T61, T76, T91, T121, T151, and T181. If EPT testing of a target tooth is not possible (e.g., missing or does not meet inclusion criterion #2) tooth substitution is permissible. For molar teeth, #2 may replace #3 and #15 may replace #14. For premolar teeth, #5 may replace #4 and #12 may replace #13. The same replacements will be made for all testing sessions, and the actual teeth tested will be documented in the CRF.

Enrollment: 48 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male or female 18 years of age or older.
• Eight representative maxillary teeth [(3 (or 2), 4 (or 5), 6, 8, 9, 11, 13 (or 12), and 14 (or15)] free of observable decay (or other pathology), crowns or veneers, all of which have EPT values of 10-50 at screening.
• Normal lip, nose, eyelid, palate, and cheek sensation.
• Patency of both left and right nasal airways.
• Ability to understand and willingness to sign the study informed consent form, communicate with study investigators, and understand and comply with the requirements of the study protocol.

Exclusion criteria

• Poorly controlled hypertension (blood pressure greater than 150/90 mmHg) or history of coronary heart disease.
• Diabetes mellitus.
• Any active thyroid disease other than S/P thyroidectomy on thyroid hormone replacement with TSH values in the normal range.
• History or presence of narrow-angle glaucoma.
• Prostatic enlargement.
• History of sinus/nasal surgery that, in the opinion of the investigator, could confound study results.
• History of frequent nose bleeds.
• Receipt of dental care requiring a local anesthetic within the last 24 hours.
• History of allergy to or intolerance of tetracaine, benzyl alcohol, benzocaine, other ester local anesthetics, succinylcholine, or para-aminobenzoic acid (as found in PABA-containing sunscreens).
• History of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or sulfite antioxidants.
• History of drug abuse.
• Use of a monoamine oxidase inhibitor within the 3 weeks immediately prior to anticipated study participation.
• Nursing, pregnant, suspected of being pregnant, or trying to become pregnant. (Females will be required to undergo pregnancy testing to rule out pregnancy)
• Use of any investigational drug and/or participation in a clinical research trial within 30 days of the first study dosing day.
• Requirement for uninterrupted use of any medication with actions that might, in the opinion of the involved investigator, confound interpretation of study results.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

48 participants in 4 patient groups, including a placebo group

Kovacaine Mist

Experimental group

Description:

3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in each nostril (bilateral dosing) administered 4 minutes apart

Treatment:

Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Kovacaine Mist and Placebo

Active Comparator group

Description:

3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing) administered 4 minutes apart

Treatment:

Drug: Placebo spray

Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Placebo and Kovacaine Mist

Active Comparator group

Description:

3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the left nostril and 3 sprays of placebo in the right nostril (left-sided dosing) administered 4 minutes apart

Treatment:

Drug: Placebo spray

Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%

Placebo spray

Placebo Comparator group

Description:

3 sprays of placebo in each nostril administered 4 minutes apart

Treatment:

Drug: Placebo spray